14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
OLMA vs ANNX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
OLMA Wins Head-to-Head Institutional Verdict (2–2 across 6 Pillars · 2–3 Matrix Metrics)
OLMA Overall Winner
6-Pillar Tally: OLMA 2 – 2 ANNX (2 Tie)
Matrix Metrics: OLMA 2 – 3 ANNX
As of Nov 17, 2026, Olema Pharmaceuticals, Inc. (OLMA) is the stronger overall head-to-head candidate over Annexon, Inc. (ANNX) in the Tradestie Institutional Equity Comparison Engine, winning 2–3 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow). OLMA carries a Unified Composite Score of 43.8/100 (HOLD) at $7.15 (N/M Forward P/E, 0.0% operating margin), whereas ANNX carries 43.5/100 (HOLD) at $3.48 (N/M Forward P/E, 0.0% operating margin).
Technical & Structure Timing Caution: OLMA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.8); meanwhile ANNX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on OLMA vs ANNX. Trailing 12-month operating profitability (OLMA 0.0% vs ANNX 0.0%) and valuation multiples (OLMA N/M vs ANNX N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $747.8M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ OLMA vs ANNX Key Questions & Quantitative Answers
As of Nov 17, 2026, Olema Pharmaceuticals, Inc. (OLMA) is the stronger overall head-to-head candidate over Annexon, Inc. (ANNX) in the Tradestie Institutional Equity Comparison Engine, winning 2–3 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow). OLMA carries a Unified Composite Score of 43.8/100 (HOLD) at $7.15 (N/M Forward P/E, 0.0% operating margin), whereas ANNX carries 43.5/100 (HOLD) at $3.48 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: OLMA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.8); meanwhile ANNX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ANNX leads the Growth & Scale pillar: OLMA posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with ANNX at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, OLMA generates N/A in USD-normalized revenue versus N/A for ANNX. In operating R&D and SG&A reinvestment, OLMA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ANNX.
OLMA and ANNX trade at balanced relative valuation multiples. OLMA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas ANNX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against OLMA (-69.8% ROE) versus ANNX (-130.8% ROE) capital efficiency.
In options market volatility and institutional positioning, OLMA carries 164.8% implied volatility (18th %ile, Compressed (<25th %ile)), a 18.47x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.81β · 83% Vol realized risk). By comparison, ANNX carries 569.3% implied volatility (100th %ile, Extreme (>80th %ile)), a 0.09x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.69β · 63% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.